|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Abbott, of Abbott Park, Ill, said the European Medicine Agency's Committee for Medicinal Products for Human Use has recommended approval of Humira (adalimumab) for the treatment of severe Crohn's disease. Marketing approval is expected within 60 days. The company also said the FDA has given Humira priority review status for the treatment of moderately to severely active Crohn's disease. Humira is a fully human monoclonal antibody already approved for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in the U.S. and Europe.
o Acacia Research Corp., of Newport Beach, Calif., said its CombiMatrix Corp., of Mukilteo, Wash., has ...
Related newspaper, magazine, and journal articles:
|
|
Article: Roche Spearheads Diagnostics Effort.(partnership with ...
Chemical Market Reporter;
July 9, 2001 ;
700+ words
... ... BOOSTING ITS presence in genetics-based research, Roche Holding AG will develop biochip technologies in collaboration with CombiMatrix Corp. Roche says the recent completion of the Human Genome Project has opened the market for customizable biochips. CombiMatrix ...
|
|